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RNA-based drugs depend on chemical modifications to increase potency and nuclease sta-1 
bility, and to decrease immunogenicity in vivo. Chemical modification will likely improve 2 
the guide RNAs involved in CRISPR-Cas9-based therapeutics as well. Cas9 orthologs are 3 
RNA-guided microbial effectors that cleave DNA. No studies have yet explored chemical 4 
modification at all positions of  the crRNA guide and tracrRNA cofactor. Here, we have iden-5 
tified several heavily-modified versions of  crRNA and tracrRNA that are more potent than 6 
their unmodified counterparts. In addition, we describe fully chemically modified crRNAs 7 
and tracrRNAs (containing no 2'-OH groups) that are functional in human cells. These de-8 
signs demonstrate a significant breakthrough for Cas9-based therapeutics since heavily 9 
modified RNAs tend to be more stable in vivo (thus increasing potency). We anticipate that 10 
our designs will improve the use of  Cas9 via RNP and mRNA delivery for in vivo and ex vivo 11 
purposes.   12 
CRISPR RNA-guided genome engineering has revolutionized research into human genetic disease and 13 
many other aspects of  biology. Numerous CRISPR-based in vivo or ex vivo genome editing therapies are 14 
nearing clinical trials. At the heart of  this revolution are the microbial effector proteins found in class II 15 
CRISPR-Cas systems1 such as Cas9 (type II) and Cas12a/Cpf1 (type V).2-4   16 
The most widely used genome editing tool is the type II-A Cas9 from Streptococcus pyogenes strain SF370 17 
(SpyCas9)2. Cas9 forms a ribonucleoprotein (RNP) complex with a CRISPR RNA (crRNA) and a trans-18 
activating crRNA (tracrRNA) for efficient DNA cleavage both in bacteria and eukaryotes (Figure 1A). The 19 
Figure 1: Initial screening of chemical modifications in the crRNA. A. Schematic of Cas9 RNP paired with target DNA. 
The secondary structure elements of crRNA and tracrRNA are labeled. RNA is shown in orange, whereas DNA is in grey. 
The PAM sequence is highlighted red and cleavage sites are marked with arrows. B. Chemical modifications used in this 
study. C. Bar graph showing mCherry-positive cells after nucleofection of HEK293T-TLR cells with RNPs that included 
the indicated crRNAs and an unmodified tracrRNA. Error bars represent standard deviation (SD) resulting from at least 
three biological replicates. 
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crRNA contains a guide sequence that directs the Cas9 RNP to a specific locus via base-pairing with the 20 
target DNA to form an R-loop. This process requires the prior recognition of  a protospacer adjacent motif  21 
(PAM), which for SpyCas9 is NGG. R-loop formation activates the His-Asn-His (HNH) and RuvC-like 22 
endonuclease domains that cleave the target strand and the non-target strand of  the DNA, respectively, 23 
resulting in a double-strand break (DSB). 24 
For mammalian applications, Cas9 and its guide RNAs can be expressed from DNA (e.g. a viral vector), 25 
RNA (e.g. Cas9 mRNA plus guide RNAs in a lipid nanoparticle), or introduced as an RNP.  Viral delivery 26 
of  Cas9 results in efficient editing, but can be problematic because long-term expression of  Cas9 and its 27 
guides can result in off-target editing, and viral vectors can elicit strong host immune responses.5 RNA and 28 
RNP delivery platforms of  Cas9 are suitable alternatives to viral vectors for many applications and have 29 
recently been shown to be effective genome editing tools in vivo.6,7 RNP delivery of  Cas9 also bypasses the 30 
requirement for Cas9 expression, leading to faster editing. Furthermore, Cas9 delivered as mRNA or RNP 31 
exists only transiently in cells and therefore exhibits reduced off-target editing. For instance, Cas9 RNPs 32 
were successfully used to correct hypertrophic cardiomyopathy (HCM) in human embryos without measur-33 
able off-target effects.8   34 
The versatility of  Cas9 for genome editing derives from its RNA-guided nature. The crRNA of  SpyCas9 35 
used in this study consists of  a 20-nt guide region followed by a 16-nt repeat region (Figure 1A). The tra-36 
crRNA consists of  an anti-repeat region that pairs with the crRNA, and also includes three stem-loops. All 37 
of  these secondary structure elements are required for efficient editing in mammalian systems.9 However, 38 
unmodified RNAs are subject to rapid degradation in circulation and within cells.10,11 Therefore, it is highly 39 
desirable to chemically protect RNAs for efficient genomic editing in hard-to-transfect cells and in vivo. Thus, 40 
it has been previously reported that chemical modifications in the crRNA and tracrRNA enhance stability 41 
and editing efficiency in vivo and ex vivo .6,7,11-13 Chemical modifications including 2'-O-methyl (2'-OMe), 42 
phosphorothioate (PS), 2'-O-methyl thioPACE (MSP), 2'-fluoro RNA (2'-F-RNA) and constrained ethyl (S-43 
cEt) have previously been employed to synthesize crRNA and tracrRNA.6,11,12 The modified RNAs not only 44 
improved Cas9 efficacy, but in some instances also improved specificity.11,14 Modifications were either based 45 
on the crystal structures of  Cas9 or limited to the ends of  RNAs, and the guides were not modified exten-46 
sively. Nonetheless, heavily or fully modified RNAs may have advantages in vivo.10 Modified siRNAs and 47 
ASOs substantially improve stability and potency, and can also reduce off-target effects. Furthermore, ex-48 
tensively modified RNAs can prevent innate immune responses.15     49 
In the present study, we sought to extensively modify the crRNA and tracrRNA while retaining the efficacy 50 
of  SpyCas9-based genome editing in cultured human cells. We used structure-guided and systematic ap-51 
proaches to introduce 2'-OMe-RNA, 2'-F-RNA and PS modifications (Figure 1B) throughout guide RNAs 52 
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(Table S1). Our strategy yielded active RNP complexes with both extensively and fully modified versions of  53 
crRNAs and tracrRNAs. 54 
Crystal structures of  SpyCas9 have been solved as the RNP alone or bound to one or both strands of  55 
target DNA.16-19 These structures provide detailed information regarding the interactions between the Cas9 56 
protein and crRNA:tracrRNA complex. We used these structures to identify sites where Cas9 protein makes 57 
no contacts with the crRNA or tracrRNA. Thus, in our initial screen, 2'-OMe modifications were intro-58 
duced at guide positions 7-10 and 20 (C2, Figure 1C). Similarly, positions 21 and 27-36 in the crRNA repeat 59 
region were also modified using 2'-OMe. To improve nuclease stability, PS modifications were also intro-60 
duced at the 5' end of  the crRNA, yielding the C3 design (Figure 1C and Table 1). In parallel, we tested a 61 
crRNA that was more aggressively modified to leave only nine nucleotides (nt) unprotected (C1). Similarly, 62 
2'-OMe modifications were also introduced into the tracrRNA at all positions where no protein contact with 63 
the RNA is observed. This gave rise to T1 that is 50% chemically modified (Figure 2 and Table 2). 64 
Table 1: Chemically modified crRNAs used in this study 65 
 66 
 Guide Repeat 
C1 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C2 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C3 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C4 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C5 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C6 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C7 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C8 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C9 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C10 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C11 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C17 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C18 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C19 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C20 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C21 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
C22 GGUGAGCUCUUAUUUGCGUA GUUUUAGAGCUAUGCU 
Black: 2'-OH; green: 2'-OMe; red: 2'-F; underlined: 3' PS.  67 
The crRNAs and tracrRNAs were tested in a HEK293T cell line stably expressing the traffic light reporter 68 
(TLR) system.20 The HEK293T-TLR cells were nucleofected (Neon Transfection System) with an in vitro-69 
reconstituted RNP complex of  recombinant 3xNLS-SpyCas9, crRNA and tracrRNA. The nucleofected 70 
cells were analyzed by flow cytometry for mCherry-positive cells, which reports on a subset of  non-homol-71 
ogous end-joining DSB repair events.20 As shown in Figure 1C, modified crRNAs 2 and 3 retain complete 72 
activity relative to the unmodified crRNA C0, suggesting that the modifications introduced in crRNAs 2 73 
and 3 are well tolerated by Cas9. Lipid-based delivery of  Cas9 RNP complex showed that C3 was even 74 
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more efficacious than C0 and C2 (Figure S1), which demonstrates the importance of  PS linkages at the 5’ 75 
terminus of  the crRNA. Similarly, T1 did not hinder Cas9 activity. On the other hand, the extra modifica-76 
tions introduced in C1 almost completely abolished Cas9 activity in cells. We reasoned that the 2'-OMe 77 
modifications (especially at positions 16-18 in the crRNA) are most likely to compromise Cas9 RNP activity 78 
since nt at position 16 and 18 were shown to make base-specific contacts with Arg447 and Arg71.16 The 2'-79 
OH of  G16 in the TLR crRNA is also predicted to make a hydrogen bond with Arg447. We chose C3 and 80 
T1 as a basis for further optimization. 81 
In the second round of  crRNA modification, we introduced additional 2'-OMe modifications into the 82 
first 6 nt of  C3 to yield C4 (Figure 2). In another design, 2'-OMe modifications were incorporated at posi-83 
tions 17 and 18 (C5). G16 was left unmodified because it makes base- and backbone-specific contacts with 84 
Cas9 and likely contributed to the low efficacy of  C1. Recently, others have also observed similar constraints 85 
at position 16.6 In C6, the importance of  2'-OH groups at positions 25 and 26 was tested. The 2'-OH of  86 
these nts contacts the protein in the crystal structure; however, they do not pair with the target DNA, and 87 
2'-OMe substitution at these positions may therefore be more tolerable. C7 and C8 were identical to C5 88 
and C6, respectively, except that they also contained 2'-OMe modifications in the first six positions. All of  89 
these crRNAs (C4-C8) were designed to identify modifications responsible for the lower activity of  C1 90 
relative to C3.  91 
As shown in Figures 2 and S2, C4-C7 retain almost the same efficacy as C0, but C8 activity was strongly 92 
reduced. These results indicated that nts at positions 1-6 and 17-18 tolerate 2'-OH substitutions. 2'-OMe 93 
modifications at positions 25 and 26 were tolerated in C6 but not in C8. We had also synthesized a version 94 
of  C8 that contained PS linkages at several unprotected positions including 15-16, 19 and 21-23 (C9). This 95 
design also exhibited reduced editing efficiency by Cas9. When tested for DNA cleavage activity in vitro, C8 96 
and C9 were fully active even at low RNP concentrations (Figure S3). These results suggest structural per-97 
turbations in C8 and C9 that are particularly acute under intracellular conditions. 98 
Figure 2: Second round of chemical optimization of crRNA (A) and tracrRNA (B). Each crRNA was tested with the un-
modified tracrRNA T0, whereas each tracrRNA was tested with the unmodified crRNA C0. The bar graphs show the 
percent of cells expressing mCherry, ± SD. Each RNA was tested in triplicate. 
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We also incorporated 2'-F-RNAs in this round of  optimization since they can increase thermal and nu-99 
clease stability of  RNA:RNA or RNA:DNA duplexes, and they also interfere minimally with C3'-endo sugar 100 
puckering.21,22 2'-F may be better tolerated than 2'-OMe at positions where the 2'-OH is important for 101 
RNA:DNA duplex stability. For these reasons, we synthesized two crRNAs based on C9 but with 2'-F mod-102 
ifications at positions 11-14 and/or 17-18 (C10-C11). These modifications rescued some of  C9’s dimin-103 
ished activity. In fact, C10 (which contained 2'-F substitutions at positions 11-14 and 17-18) performed 104 
better than C11, in which positions 17-18 were unmodified. Our results suggest that 2'-F substitutions can 105 
compensate for lost efficacy resulting from high 2'-OMe content. It is especially noteworthy that C10 retains 106 
the same activity as the unmodified C0 but contains at least one backbone modification at every single 107 
phosphodiester linkage. This represents a significant breakthrough for Cas9-based therapeutics because 108 
C10 has great potential to provide increased stability, and therefore more efficient editing, in vivo. 109 
Table 2: The tracrRNA sequences used in this study 110 
 Anti-Repeat Stem-loop 1 Linker Stem-loop 2 Stem-loop 3 
T1 AGCAUAGCAAGUUAAAAU AAGGCUAGUCC GUUAUCA ACUUGAAAAAGUG GCACCGAGUCGGUGCUUU 
T2 AGCAUAGCAAGUUAAAAU AAGGCUAGUCC GUUAUCA ACUUGAAAAAGUG GCACCGAGUCGGUGCUUU 
T3 AGCAUAGCAAGUUAAAAU AAGGCUAGUCC GUUAUCA ACUUGAAAAAGUG GCACCGAGUCGGUGCUUU 
T4 AGCAUAGCAAGUUAAAAU AAGGCUAGUCC GUUAUCA ACUUGAAAAAGUG GCACCGAGUCGGUGCUUU 
T6 AGCAUAGCAAGUUAAAAU AAGGCUAGUCC GUUAUCA ACUUGAAAAAGUG GCACCGAGUCGGUGCUUU 
T7 AGCAUAGCAAGUUAAAAU AAGGCUAGUCC GUUAUCA ACUUGAAAAAGUG GCACCGAGUCGGUGCUUU 
T8 AGCAUAGCAAGUUAAAAU AAGGCUAGUCC GUUAUCA ACUUGAAAAAGUG GCACCGAGUCGGUGCUUU 
Black: 2’-OH; green: 2’-OMe; red: 2’-F; underlined: 3’ PS.  111 
We also carried out a second round of  tracrRNA optimization. T1 was further modified by introducing 112 
2'-OMe substitutions at most positions where the 2'-OH groups do not make crystal contacts with the pro-113 
tein. In addition, some nts that interact with Cas9 were also modified, given that the crRNA tolerated sub-114 
stitutions at many such positions. This approach produced tracrRNAs T2-T5, which contain modifications 115 
in at least 55 out of  67 nt. A15 is the only position that differs between T2 and T4 whereas T3 contains 116 
additional stabilizing PS linkages at unprotected positions relative to T2. These tracrRNAs were tested in 117 
HEK293T-TLR cells, and the majority of  2'-OMe chemical modifications were tolerated by the tracrRNA 118 
except at position A15 (Figure 2). In the crystal structure, the 2'-OH of  A15 interacts with Ser104. The best-119 
performing tracrRNA from this round was T2, which contains 12 unmodified positions. Furthermore, the 120 
inclusion of  PS linkages at these 12 positions reduced but did not abolish activity. This design (T3) contains 121 
at least one chemical modification at every position (either a PS or ribose modification). This also represents 122 
an important advance for therapeutic applications of  Cas9.   123 
The mCherry signal only results from indels producing a +1 frameshift, and therefore underestimates true 124 
editing efficiencies. To ensure that crRNA:tracrRNA combinations do not yield false negatives by favoring 125 
TLR indels that are out of  the mCherry reading frame, we also carried out Tracking of  Indels by Decom-126 
position (TIDE) analysis to analyze overall editing efficiencies. As shown in Figure S2, editing efficiencies 127 
measured using TIDE correlate well with the mCherry signal. 128 
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 We also explored whether addition of  terminal modifications such as fluorophores, N-Acetylgalactosa-129 
mine (GalNAc), or Cholesterol-Triethylene glycol (TEGChol) are tolerated by the crRNA and the tra-130 
crRNA. Such modifications can be useful for microscopy, and for monitoring cellular or tissue-specific RNA 131 
uptake. We introduced 5'-Cy3 modifications on crRNAs C10 and C11 to yield C12 and C13, respectively 132 
(Table S1). We also covalently attached TegChol or GalNAc to the 3' end of  C12 or C13 to obtain C14 133 
and C15, respectively. Most crRNA modifications were tolerated on both ends, though some loss of  function 134 
was observed with C13, C14 and C16 (Figure S2). In contrast, C15 was essentially inactive. T5 containing 135 
a 3'-TegChol was also nonfunctional, not surprisingly given the 2'-OMe substitution at A15. 136 
We built upon the best-performing individual chemical configurations (C10 and T2) to attempt to define 137 
combined crRNA:tracrRNA modification patterns that are compatible with SpyCas9 RNP function. Be-138 
cause crRNA 2'-F substitutions were largely tolerated (Figure 2), and in some cases even compensated for 139 
the loss of  efficacy caused by 2'-OMe substitutions, we added several 2'-F modifications to C10 and T2. In 140 
addition, because we had observed that simultaneous 2'-OMe modification at positions 25 and 26 negatively 141 
affected efficacy in some cases (e.g. C8), we tested these two positions for their sensitivities to 2'-F or indi-142 
vidual 2'-OMe substitutions. We also incorporated additional 2'-F modifications in the tracrRNAs. In posi-143 
tions where the nucleobases interact with Cas9, we took two approaches to modification. While we suspected 144 
that protein-interacting sites would be less tolerant of  modification, it was difficult to predict whether steric 145 
constraints or charge interactions were more important. To address this issue, we synthesized three different 146 
tracrRNAs: one where all protein interacting sites were left as 2'-OH (T6), another where all were converted 147 
to 2'-F (T8), and another where only the nucleobases that interact with nonpolar amino acids were con-148 
verted to 2'-F (T7). Using this systematic approach, crRNAs C17-C22 and tracrRNAs T6-T8 were syn-149 
thesized and tested (Figure 3A). 150 
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When C17-C22 were used with either T2 or the T0 control (20 pmol RNP), all showed comparable 151 
efficacy as the C0 and C10 crRNAs (Figure 3B). This includes the fully modified C21 that is either 2'-F- or 152 
2'-OMe-substituted at every position. To our knowledge, this is the first time a completely modified and 153 
fully functional crRNA has been reported. C21 loses some efficacy when combined with T6-T8, and is also 154 
less potent than C0 when lower (3 pmole) doses of  RNP are delivered (Figure S4). These losses may be due 155 
to compromised base pairing between the heavily modified repeat:anti-repeat duplexes. Across all tracrR-156 
NAs tested, C20 exhibits the highest editing efficiency. In addition, at 3 pmol RNP, C20 is more potent 157 
than unmodified C0, suggesting enhanced stability in cells (Figure S4). Although C20 includes six ribose 158 
sugars, each is adjacent to a PS modification, leaving no unmodified linkages in the crRNA.   159 
Among T6-T8, the best-performing tracrRNA was T6, especially with modified crRNAs including C20. 160 
The fully-modified tracrRNA (T8) compromised the potency of  all crRNAs tested, but retains some func-161 
tion (~5% editing with 20 pmol RNP) with C19 and C20 (Figure 3B). To test whether the T8 activity 162 
improves at higher doses, we nucleofected cells with 100 pmol Cas9 RNP. We found that by using a higher 163 
amount of  Cas9 RNP, the editing efficiency of  T8 in combination with C0 or C20 is rescued to the same 164 
level as observed using 20 pmol of  Cas9 RNP with C0:T0 (Figure 3). Furthermore, at higher doses, the 165 
efficacy of  C20:T8 is almost as high as that of  C20:T0. Lastly, the editing efficiency of  the fully-modified 166 
pair (C21:T8) is within ~2-fold of  the unmodified (C0:T0) crRNA:tracrRNA pair. To our knowledge, this 167 
is the first demonstration of  efficient editing activity with a fully-modified crRNA:tracrRNA combination. 168 
While the editing efficiency is not as high as that of  the unmodified RNAs in cells, the increased serum 169 
Figure 3: Cas9 tolerates heavily- and fully-modified crRNA:tracrRNA. A & B. Each crRNA was tested with tracrRNAs T0, 
T2, and T6-T8 using 20 pmol of Cas9 RNP. C. HEK293T-TLR cells were also nucleofected with 100 pmol of the indicated 
RNPs to test whether heavily modified RNAs regain functionality at higher doses. Error bars show ± SD of three biological 
replicates. 
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stability afforded by the fully chemically optimized C21:T8 combination (Figure S5) would likely provide 170 
significant benefits in vivo, as observed for fully modified siRNAs and ASOs. 171 
To verify that our crRNA designs are compatible with different guide sequences, including those targeting 172 
endogenous human genes, we tested the C10, C20 and C21 designs targeting the huntingtin (HTT), human 173 
hemoglobin β (HBB), and Vascular Endothelial Growth Factor A (VEGFA) genes.14,23 VEGFA and HBB target 174 
sites were chosen for their therapeutic potential as well as the fact that they have been previously validated 175 
for genome editing. The HTT site, on the other hand, is a potential polymorphic target for Huntington’s 176 
disease treatment. As shown in Figure 4A & 4B, HTT-C10 and HTT -C20 performed as well as the mini-177 
mally modified HTT-C0 when paired with T2 and T0. T6 and T7 are more efficacious with the modified 178 
C10 compared to minimally modified C0. The fully modified HTT-C21 performed as well as the HTT-179 
C0 when tested with T2. However, similar to the TLR target site, some loss of  potency is observed with the 180 
fully modified T8. However, T8 did support editing with efficiencies comparable to T0 when paired with 181 
C20. Similar results were obtained at the HBB and VEGFA target sites (Figure 4C & 4D): our potent RNA 182 
designs (C20:T2) performed as well as the minimally modified designs, and the fully modified dual guides 183 
exhibited some loss in potency. Furthermore, nucleofections performed using 3 pmol of  RNP suggested that 184 
C10 and C20 may be more efficacious (but never less efficacious) than the unmodified crRNA, similar to 185 
what was observed in Figure S4, but this effect seemed to vary between target sites (Figure S8). C20 also 186 
showed higher potency compared to C0 when tested in human embryonic stem cells (hESC) (Figure 4E). 187 
In hESC the highest potency was achieved using the heavily modified combination C20:T2. Furthermore, 188 
the fully modified crRNA C21 was just as efficacious as the minimally modified C0. We also examined 189 
editing in HEK293T cells at the top off-target site for both HBB and VEGFA, as validated previously.14,23 190 
The modified crRNAs do not significantly affect off-target editing, though the fully modified C21:T8 may 191 
provide slight specificity improvements compared to the less heavily modified designs (Figure S9). Collec-192 
tively these results demonstrate that our modified crRNA designs can be applied to endogenous target sites. 193 
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 194 
 195 
 196 
 197 
It has previously been shown that crRNA and tracrRNA can be fused with a GAAA tetraloop or other 198 
linkers to yield a single guide RNA (sgRNA) with enhanced efficacy. Given the possibility that repeat:anti-199 
repeat interactions could affect efficacy, we explored the pairing between the repeat and anti-repeat of  200 
crRNA and tracrRNA. We designed and synthesized GC-rich crRNAs (hiGC C1-C4) and tracrRNAs 201 
(hiGC T1-T4) to improve pairing between crRNA and tracrRNA (Table S1). All of  the modified RNAs 202 
outperformed in vitro-transcribed sgRNA as well as synthetic, unmodified dual RNAs (Figure S6). Further-203 
more, at lower concentrations, hiGC-C1 exhibit increased potency relative to non-optimized versions of  204 
unmodified or modified RNAs (Figure S6). However, this trend does not hold true in HTT-hiGC C1 (Figure 205 
S6). Therefore, these mutant sequences may be superior to wild-type sequences in a guide-sequence-specific 206 
manner. 207 
In summary, we used a structure-guided approach combined with systematic addition of  modifications to 208 
identify heavily- or fully-modified crRNAs and tracrRNAs that direct SpyCas9 genome editing in human 209 
cells. Two pairs of  crRNA:tracrRNA stand out as particularly promising. First, C20:T2 is our most potent 210 
combination, and both RNAs contain ribose substitutions at >80% of  their nts. Furthermore, C20 contains 211 
at least one chemical modification (2'-OMe, 2'-F or PS) at every single position. The C20:T2 combination 212 
is more potent than its unmodified crRNA:tracrRNA counterpart when tested in human cells. Second, 213 
although the C21:T8 combination exhibits reduced potency in human cells, its significant functionality is 214 
still noteworthy because it is completely devoid of  ribose sugars. This will greatly ease chemical synthesis, 215 
Figure 4: Targeting endogenous genes with modified RNAs.  A. The C10 guide design targeting HTT exon 50 was tested 
using 20 pmol of RNP along with T2 and T6-T8 in HEK293T cells. B. HTT-C20 and HTT-C21 designs were tested using 
80 pmol of Cas9 RNP with the indicated tracrRNAs. C. The therapeutically relevant HBB locus was targeted using a previously 
validated guide sequence incorporated into the C20 design. D-E. VEGFA-targeting crRNAs C20 and C21 were tested using 
the indicated tracrRNAs with 80 pmol of RNP in HEK293T (D) cells or hESCs (E). Bars show averages (±SD) of at least three 
biological replicates. 
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enhance in vivo stability, and provide a springboard toward additional improvements (such as terminally 216 
appended chemical functionalities) that facilitate delivery and efficacy during clinical applications of  ge-217 
nome editing.  218 
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